Publications found:
2,622
Sort by:
Glass Packaging Market in Switzerland
US$ 649.00
... This market study answers to questions such as: What is the size of the glass packaging market in Switzerland? How is the market divided into different types of products? Which products are growing fast? How the market has been developing? How does the future look like? What is ...
December 2012
20 pages
PESTLE Analysis of Switzerland 2013, December 2012
US$ 750.00
... , has conducted an analysis of the political, economic, social, technological, legal, and environmental conditions of Switzerland and presents its findings in “PESTLE Analysis of Switzerland 2013.” The report outlines ... features of “PESTLE Analysis of Switzerland 2013” include: Trend and forecast for key macroeconomic variables that are useful to make major investment decision Analysis on economic activity ...
December 2012
103 pages
BASILEA, Ceftobiprole – A Free Option?
US$ 140.00
... for opportunities in “Drugs for Bad Bugs”, we reinstate our coverage on Basilea Pharma (BSLN), as it is trading close to cash value and offers a favorable ... our initiation report released on 9th July, 2012 on BSLN titled “Ceftobiprole - A Free Option?
July 2012
8 pages
Novartis, ACZ885 – Impressive data in SJIA, but no meaningful commercial opportunity
US$ 90.00
Novartis today reported positive Phase 3 data on ACZ885 (canakinumab) in SJIA. The data is impressive but commercial opportunity would be limited as SJIA is a rare disease, while ... 20000 or less depending on the weight. While if NVS chose to price ACZ885 at its existing annual cost ($100,000), it may not be able ...
June 2012
1 pages
NOVARTIS
US$ 90.00
For the fourth quarter 2011, in line with our expectations, NVS Sales grew 5%, and core EPS advanced 8%. NVS also announced full year dividend for 2011 at CHF 2.25, which translates into a meager 2%, increase, which we think is a dampener. The 2012 guidance as well was lackluster as NVS expects net sales in ...
January 2012
2 pages
NOVARTIS - Tekturna: ALTITUDE study in high risk hypertensive patients TERMINATED
US$ 90.00
... the termination of large PhIII study (ALTITUDE) due to higher rate of adverse events and no benefits observed for patients taking Tekturna in addition to ACE ... inhibitors. Post this announcement, NVS will cease promotion of Tekturna/Tekturna products in combination with ACE inhibitors/ARB inhibitors. The event ...
December 2011
1 pages
ROCHE, GLAXOSMITHKLINE - Exciting Data on TDM1 - Will Keep Competition at Bay
US$ 140.00
... months compared to Herceptin + docetaxel (14.2 m vs. 9.2 m- Table 1). The safety data as well, is very convincing as T-DM1 cut Grade 3 or more adverse effects ... 50% (46.4% vs. 89.4%). With T-DM1 and pertuzumab arrows in its quiver, Roche is well poised to sustain its breast cancer franchise beyond Herceptin ...
September 2011
4 pages
Roche, BMY - Zelboraf (Vemurafenib) approval- Competition to YERVOY starts
US$ 90.00
The USFDA approval of Zelboraf (Vemurafenib) for inoperable metastatic melanoma, well in advance of the PDUFA date is encouraging. USFDA has also approved the cobas BRAF mutation diagnostic test. This will reduce YERVOY uptake directly as ~50% of Metastatic Melanoma patients are B-RAF positive and Zelboraf ...
August 2011
2 pages
Novartis vs. Peer group- Growth rate differential to widen going forward
US$ 90.00
Novartis reported solid revenue growth driven by Sandoz, recently launched products and Alcon Acquisition. Going ... shape up in the longer term. Novartis is in better position to return back profits to investors compare to its global peers in unfavorable environment mainly due to its ...
July 2011
2 pages
NOVARTIS, NVA237 ready to enter LAMA market: Spiriva domination under threat!!
US$ 90.00
... daily LAMA), meeting both, primary and the secondary endpoints. NVA237 demonstrated comparable safety and efficacy data vs. PFE’s Spiriva (once ... antimuscarinic side effects is potentially how, NVS might pitch NVA237 against Spiriva. We expect NVA237 to garner upto 25% of the LAMA market growing approximately ...
June 2011
2 pages
ASCO-2011 – RG7204 Vs Ipilimumab : The first line Dilemma persists
US$ 140.00
... the detailed data from phase III pivotal studies on RG7204 and ipilimumab respectively. With the overall survival data on ... comparable, physician is likely to weigh ipilimumab’s superior durability of response compared to RG7204 (19.3m vs 6.7m) on one side with its inferior toxicity profile (56% vs 10% ≤ Grade ...
June 2011
2 pages
Tarcva - EURTAC Data positive: Threat to Iressa in Firstline NSCLC
US$ 140.00
... by 63 % compared to chemotherapy (9.7 m vs 5.2 m). Interim analysis of EURTAC trial showed that Tarceva improved the overall survival by 4 m (22.9 m ... vs 18.8 m) compared to cisplatin chemotherapy. The data poses threat to AZN’s Iressa as it has not demonstrated OS ... lines of EGFR positive advanced NSCLC.
June 2011
2 pages
Switzerland Insurance Market Intelligence: 2011 Edition
US$ 600.00
... retirement products would gain importance driving the overall insurance industry of Switzerland. With the economic crisis every sector saw a decline in the ... segments life as well as non-life market. Swiss Life accounting for approximately 29.6% of the total life insurance segment is the second largest players ...
January 2011
21 pages
Switzerland: Agrochemicals: Market Intelligence (2020-2025)
US$ 2,250.00
... The report “Switzerland: Agrochemicals: Market Intelligence (2018-2022)” provides market intelligence on the different market segments, based on type, active ingredient, formulation, crop, and pest. Market size and forecast (2018-2022) has ...
June 2025
120 pages
